Full name :
First name :
Mail :
Zip Code :
City :
Country :
Email :
Phone :
Fax :
Website :
Directory :
| Title : The lipoprotein-associated phospholipase A2 inhibitor Darapladib sensitises cancer cells to ferroptosis by remodelling lipid metabolism - Oh_2023_Nat.Commun_14_5728 |
| Author(s) : Oh M , Jang SY , Lee JY , Kim JW , Jung Y , Kim J , Seo J , Han TS , Jang E , Son HY , Kim D , Kim MW , Park JS , Song KH , Oh KJ , Kim WK , Bae KH , Huh YM , Kim SH , Han BS , Lee SC , Hwang GS , Lee EW |
| Ref : Nat Commun , 14 :5728 , 2023 |
| Abstract : Oh_2023_Nat.Commun_14_5728 |
| ESTHER : Oh_2023_Nat.Commun_14_5728 |
| PubMedSearch : Oh_2023_Nat.Commun_14_5728 |
| PubMedID: 37714840 |
| Title : A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naive patients with type 2 diabetes - Yang_2015_Endocr.J_62_449 |
| Author(s) : Yang HK , Min KW , Park SW , Chung CH , Park KS , Choi SH , Song KH , Kim DM , Lee MK , Sung YA , Baik SH , Kim IJ , Cha BS , Park JH , Ahn YB , Lee IK , Yoo SJ , Kim J , Park Ie B , Park TS , Yoon KH |
| Ref : Endocrine Journal , 62 :449 , 2015 |
| Abstract : Yang_2015_Endocr.J_62_449 |
| ESTHER : Yang_2015_Endocr.J_62_449 |
| PubMedSearch : Yang_2015_Endocr.J_62_449 |
| PubMedID: 25819061 |
| Title : Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension - Jin_2015_Diabetes.Obes.Metab_17_511 |
| Author(s) : Jin SM , Park SW , Yoon KH , Min KW , Song KH , Park KS , Park JY , Park IB , Chung CH , Baik SH , Choi SH , Lee HW , Lee IK , Kim DM , Lee MK |
| Ref : Diabetes Obes Metab , 17 :511 , 2015 |
| Abstract : Jin_2015_Diabetes.Obes.Metab_17_511 |
| ESTHER : Jin_2015_Diabetes.Obes.Metab_17_511 |
| PubMedSearch : Jin_2015_Diabetes.Obes.Metab_17_511 |
| PubMedID: 25523633 |